Glucoplus

Glucoplus is a prescription oral medication containing metformin hydrochloride, a biguanide antidiabetic agent. It is formulated for oral administration and is marketed in the European Union. Metformin works by decreasing hepatic glucose production and improving peripheral insulin sensitivity, helping to control blood glucose levels in adults with type 2 diabetes mellitus. The product is available only with a prescription and is currently not a controlled substance.

Glucoplus is indicated for the management of hyperglycemia in patients with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

- As monotherapy in patients newly diagnosed with type 2 diabetes when diet and exercise alone are insufficient. - In combination with other oral antidiabetic agents (e.g., sulfonylureas, DPP‑4 inhibitors) to achieve additional glycemic control. - As adjunct therapy with insulin to reduce insulin dose requirements. - For patients with overweight or obesity where metformin’s weight‑neutral or modest weight‑loss effect is beneficial.

Like other metformin products, Glucoplus may cause a range of adverse effects. Most are mild and transient, such as gastrointestinal symptoms, while rare serious reactions require prompt medical attention.

Common: - Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea. - Metallic taste in the mouth. - Decreased appetite. - Mild headache. - Transient dizziness or light‑headedness.

Serious: - Lactic acidosis, a rare but potentially fatal metabolic complication. - Severe skin reactions including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Persistent vomiting leading to dehydration. - Hypersensitivity reactions such as rash or pruritus.

Healthcare providers should evaluate several factors before prescribing Glucoplus to ensure safe and effective use.

- Assess renal function; metformin is contraindicated in severe renal impairment. - Monitor liver function, as hepatic disease may increase risk of lactic acidosis. - Use caution in patients with heart failure or a history of hypoxia. - Adjust dose or discontinue before any radiologic procedures that use iodinated contrast agents. - Review pregnancy and lactation status; metformin is generally avoided unless benefits outweigh risks. - Evaluate for alcohol abuse, which can potentiate lactic acidosis. - Consider age‑related changes in renal clearance when dosing older adults.

Glucoplus can interact with several medications, affecting its efficacy or safety profile.

Avoid: - Iodinated contrast media administered intra‑arterially or intravenously. - Cimetidine, which can increase metformin plasma concentrations. - Certain antiretroviral drugs (e.g., didanosine) that raise the risk of lactic acidosis. - Trimethoprim, which may increase metformin concentrations.

Use with caution: - Diuretics that may affect renal function. - ACE inhibitors or ARBs in patients with compromised kidney function. - Alcohol consumption, which can predispose to metabolic acidosis. - Beta‑blockers, as they can mask hypoglycemia symptoms. - Other antihypertensive agents that may influence renal perfusion.